The only way that we are going to know those answers is through the investigation. In the first year, STAR enrolled 6,139 women, from the over 47,000 who went through the individualized, no-obligation risk assessment. Of the over 47,000, over 29,000 of these women were eligible based on their risk. These eligible women need to then make their choice based on their own understanding of their risk and an understanding of the two drugs' known risks and benefits. Each woman will receive an individualized risk assessment form which, in addition to providing a predicted breast cancer risk, will compare that risk to a woman who is of the same age and race, but without the increased risk factors of developing breast cancer.
Women come with a varying amount of information.
Some, after receiving the information we make available to them, go to their family members, or other women, to their primary care physicians - to discuss the idea of their participation in the trial. In considering those roles, there are efforts from various angles to try to educate primary care physicians about explaining risks and benefits of chemo-prevention. Oncologists have been doing this for quite some time. This has not been the case with primary care physicians. There was a joint effort by Zeneca, various oncologists, and NCI as well, called Discovery International, which went to various sites throughout the country to teach primary care physicians how to counsel about risks and benefits.